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of these patients receiving 3-line therapy differed significantly in Moscow and St. 
Petersburg, as compared with other regions. ConClusions: Obtained clinical and 
epidemiological data made it possible to fill in the model of management of patients 
with breast cancer in particular regions of Russia.
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objeCtives: Breast cancer is a leading cause of oncological death among Portuguese 
women but a decline in age-standardized mortality rates is well documented and 
due to an increasing frequency of early diagnosis (more than 85% of the women 
aged 45-69 years, underwent a screening mammography according to the most 
recent national health survey) and access to more efficient treatments, including 
adjuvant and neoadjuvant chemotherapy. However, certain tumor characteristics, 
such as Human epidermal growth factor receptor 2 (HER2) -positive breast cancer, 
are associated with poor prognosis for patients with both early and metastatic 
breast cancer. Methods: Previous studies showed that trastuzumab was expected 
to prevent metastases in about 700 women during 10 years if used in early breast 
cancer, in Portugal. T-DM1 significantly prolonged progression-free (3 m) and over-
all survival (6 m) compared to lapatinib plus capecitabine in patients with HER2-
positive advanced breast cancer previously treated with trastuzumab and a taxane. 
Also, the combination of pertuzumab, trastuzumab, docetaxel, as compared with 
placebo, trastuzumab, docetaxel, when used as first-line treatment for HER2-positive 
metastatic breast cancer, significantly prolonged progression-free survival. These 
trials data and population epidemiological information is used to fit predictive 
models adjusting for available confounders. Results: Although high quality data 
on patients with HER2-positive metastatic disease regarding age and other potential 
health differences is lacking, particularly in Portugal, we modeled population meas-
ures of frequency and applied data describing the clinical epidemiology of meta-
static breast cancer to anticipate the potential impact of these treatment options on 
the quality and the quantity of life of affected individuals, taking into consideration 
the period 2014-24. Additionally, by contrasting the available alternatives, we will 
present an estimation of the averted expenses regarding treatment options for the 
same period. ConClusions: The study provides information on health gains and 
evidence for decision making.
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objeCtives: The latest available published oncology national data from the Slovak 
Republic (SR) are for year 2008. The objective of this analysis was to evaluate long-
term national trends of breast cancer (BC) incidence, mortality, clinical stages and 
prevalence to obtain more actual data for the purpose of cost-of-illness studies 
and budget impact analysis in the SR. Methods: Time-trends of national data 
on incidence, mortality, clinical stages and prevalence of BC in 1978-2008 were 
analyzed by using joint-point regression (Version 4.0.4. - May 2013). The data were 
predicted to the current year 2014. The trends are presented with a correspond-
ing 95% Confidence Intervals (CI) and p-value with null hypothesis being constant 
with time. Results: In 2008, BC age-standardized incidence in the SR represented 
59.8/100,000 females (n= 2.639 cases, mean age of women= 61.9 y.), in 1978-2008 the 
incidence was increasing continuously with annual percentage change (APC) of 2.2% 
(95% CI= 2.1-2.3, p< 0.0001), estimation for 2014 is 63.8/100,000 (n= 3.081). Mortality 
in 2008 represented 15.2/100,000 (n= 751) with four join-points and decreasing trend 
from 2001 by APC -3.6% (95% CI= -7.2-0.1, p< 0.04), estimation for 2014 is 14.0/100,000 
(n= 820). National prevalence in 1978-2008 represents 22.118 cases, for 2014 estimate 
is 29.012. According to the national data, in 2014 we estimate 32.6% of patients 
diagnosed in the 1st clinical stage, 36.2% in the 2nd, 16.4% in the 3rd, 7.0% in the 
4th and 7.8% in the undefined clinical stage. The number of cases diagnosed in the 
1st clinical stage is increasing during the time. Despite the observed increase in the 
values of BC incidence, the decrease in mortality has manifested itself in recent 
years. ConClusions: Actual data on incidence, mortality, prevalence and clinical 
stages of BC in the SR can be used as the source for setting the size of population 
in cost-of-illness studies and budget impact analysis.
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objeCtives: Stage IB cutaneous melanomas are characterized by a low risk for 
recurrence and a high survival. However, empirical evidence on recurrence patterns 
and survival subsequent to recurrence is limited. We investigated overall survival 
(OS) and recurrence patterns, and assessed whether the time-to-recurrence was 
associated with prognostic factors. Methods: The Dutch Comprehensive Cancer 
Centers registry was used to identify patients diagnosed with stage IB melanoma 
between January 2003 and December 2011 in six Dutch hospitals including two 
academic and four general hospitals (n= 971). Data were retrospectively collected 
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objeCtives: Treatment of multiple myeloma (MM) consists of a consecutive appli-
cation of various treatment modalities. The optimal sequence of different treat-
ment combinations is unclear. There is a need for the establishment of an analytic 
framework comparing overall survival (OS) of different treatment sequences in MM. 
This analysis contains the first attempt to create such a framework. Methods: 
We performed a systematic literature review (SLR) on treatments compared in 
randomized controlled trials in newly diagnosed and relapsed MM patients. The 
following treatment/combinations were considered; melphalan/prednisone (MP), 
dexamethasone (D), thalidomide (T), bortezomib (V) and lenalidomide (R). Response, 
time to next treatment (TTNT) and OS data were extracted. Response rates were 
derived and pooled for each treatment and treatment line using ordered logistic 
network meta-analysis. The pooled estimates were combined in a Markov model 
framework with treatment switch and mortality transition probabilities to predict 
OS. Seventeen sequences were tested, one starting with MPR and four for each 
starting with MP, MPT, MPV and MPVT. Results: Estimations on the basis of the 
Markov model showed that median OS varied between 40-43,42-45,43,44-47 and 
46-49 months for sequences starting with MP, MPT, MPR, MPV and MPVT, respec-
tively. ConClusions: This study shows a first attempt to build an analytic frame-
work comparing OS of treatment sequences in MM. The absolute results should be 
interpreted with caution, as MM is a heterogeneous disease and the model does 
not yet capture all subtleties related to sequential treatment in clinical practice. 
However, face validity of these first results seem promising and warrant further 
development of this analytic framework.
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objeCtives: The effect of having a positive anaplastic lymphoma receptor tyrosine 
kinase (ALK) mutation on the burden of disease in Stage IV non-small cell lung 
cancer (NSCLC) is unknown. This study compared the burden of disease in ALK 
positive Stage IV NSCLC with ALK negative Stage IV NSCLC. Methods: Burden 
of disease by ALK mutation status was evaluated in Egypt, Russia, and the United 
Arab Emirates (UAE) using disability adjusted life years (DALYs). A burden of disease 
model was developed in line with World Health Organisation (WHO) guidelines. 
Epidemiological data were collected by a survey disseminated during interviews in 
at least three centres per country. Disability weights were obtained from a Dutch 
study. Discounting, age-weighting and life expectancies were based on the WHO 
reference case. Sensitivity analyses were conducted to test the level of uncertainty 
in the model results. Results: Total DALYs across the countries were lower in ALK 
positive disease compared to ALK negative disease (833 vs. 2611). On a per country 
basis, total DALYs were higher in ALK positive disease compared to ALK negative 
disease for Egypt (22 vs. 11) and UAE (229 vs. 219) but lower for Russia (582 vs. 
2381). DALYs per incident case of the disease were consistently higher across the 
countries in ALK positive disease compared to ALK negative disease (Egypt: 11.24 
vs. 10.85; Russia: 9.38 vs. 4.97; UAE: 15.29 vs. 7.82). Results were sensitive to changes 
in discounting, age-weighting, deaths, and incidences. ConClusions: The study 
would suggest that the greatest burden of disease lies in the population with ALK 
negative Stage IV NSCLC compared to ALK positive Stage IV NSCLC, although this 
finding varied between countries. However, it was consistently found that a single 
patient with Stage IV NSCLC will have a greater burden of disease if their ALK 
mutation test is positive.
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objeCtives: In Russia, breast cancer (BC) took first place in the structure of cancer 
incidence and mortality in the female population. Modern therapeutic approaches 
advanced breast cancer (ABC) can achieve clinically significant regression of symp-
toms, prolong life and improve its quality. Aim of this study was to conduct clinical 
and epidemiological analysis of reference postmenopausal patients with hormone- 
(HR+), HER2-ABC in Russia. Methods: Survey of experts from different regions 
of Russia. The questionnaire included the following questions: the proportion of 
patients with different types of breast cancer; drugs and modes of their appoint-
ment as the first, second and third-line treatment of patients postmenopausal 
HR+, HER2-ABC; hospitalization rate per year; laboratory and instrumental methods 
of research, consulting, adverse events with the use of drugs in the treatment of 
patients and their drug regimes correction. Results: From 13 regions of Russia 7 
experts refused to provide information on the questionnaire, which may indicate 
a reluctance to disclose information on the epidemiology and the tactics of the 
disease. Data were obtained from the regions - Moscow, Saint Petersburg, Republic 
of Khakassia, Omsk region, Primorsky Krai, Krasnoyarsk Krai. Share of the growth 
of new breast cancer patients is 10,5-29,6% (median 13.4%) per year. Number of 
patients with ABC from patients with breast cancer is 9,2-53% (median-30%). On 
average, 70% of patients with ABC are in menopause. Number of patients with HR+, 
ER2-ABC at the end of 2013 amounted to Moscow-1772, St. Petersburg-492, Republic 
of Khakassia-188, Omsk region-344, Primorsky Krai-358, Krasnoyarsk Krai-3471. The 
average frequency of hospitalizations in these patients is 6 times a year. Proportion 
